Vaccines Market: Routine Immunization Recovery, Adult and Older-Adult Vaccines, New RSV, Pneumococcal, and Meningococcal Products, and Outbreak Preparedness to Drive Steady Market Expansion Through 2036

The global Vaccines Market was valued at USD 58.5 billion in 2025 and is projected to expand at a steady CAGR of 5.2% to reach approximately USD 97.1 billion by 2036, driven by efforts to restore and expand routine childhood immunization, with WHO and UNICEF reporting 85% global DTP3 coverage in 2025, growth in adult and older-adult vaccines against shingles, RSV, pneumococcal disease, and influenza, new conjugate and combination vaccines, and investment in outbreak preparedness and regional vaccine manufacturing. The market encompasses vaccines by type, technology, disease indication, route of administration, age group, end user, and distribution channel. Vaccines prevent millions of deaths every year.

The Vaccines Market’s steady 5.2% CAGR reflects a mix of steady pediatric demand and growth in newer adult vaccines. WHO and UNICEF estimate that in 2025 about 110 million infants received three doses of DTP vaccine and 13.5 million children received no vaccines at all, while measles coverage of 84% for the first dose remains below the 95% needed to prevent outbreaks. Adult vaccines are a major source of value growth: GSK reported second-quarter 2026 vaccine sales of £2.28 billion, up 8% at constant exchange rates, led by meningitis vaccines and its RSV vaccine Arexvy. Public procurement through national programmes, UNICEF, and Gavi provides a stable volume base, while private markets in high-income countries generate a large share of value through newer adult vaccines. New adult vaccines and mRNA technology are expanding the market.

Executive Snapshot

What is the state of routine immunization?
WHO and UNICEF data released in July 2026 show 85% of infants completed three DTP doses in 2025, and the number of zero-dose children fell by about 750,000 to 13.5 million. However, 57 countries reported large or disruptive measles outbreaks in 2025. Restoring and expanding coverage remains a priority for governments and donors, supporting steady demand for pediatric vaccines. Gavi and national programmes aim to reach zero-dose children in conflict and remote areas. Coverage for key childhood vaccines has stalled near pre-pandemic levels in many countries.

Why are adult vaccines growing?
Ageing populations are more vulnerable to shingles, pneumonia, RSV, and influenza. New vaccines and recommendations for older adults, such as shingles vaccines, RSV vaccines, and higher-valency pneumococcal conjugate vaccines, have expanded the adult market. Adult vaccines often command higher prices than pediatric vaccines in high-income markets. Public health agencies regularly review and update adult vaccination recommendations. RSV, shingles, and pneumococcal vaccines are recommended for older adults.

How are companies performing?
GSK reported second-quarter 2026 vaccine sales of £2,284 million, with meningitis vaccines up 21% at constant exchange rates on outbreak-related demand and Arexvy more than doubling, while Shingrix grew 3%. Performance varies by product and market, as recommendations, reimbursement, and competition change. Vaccine company results are affected by tender timing and recommendation changes. Results differ across companies depending on portfolio mix and demand for COVID-19 vaccines.

What technologies are used?
Vaccines include live attenuated, inactivated, subunit, conjugate, toxoid, viral vector, and mRNA vaccines. Conjugate vaccines protect young children against pneumococcal and meningococcal disease. mRNA technology, proven during COVID-19, is being developed for influenza, RSV, CMV, and other targets. Combination vaccines reduce the number of injections children need. Platforms include live attenuated, inactivated, subunit, conjugate, viral vector, and mRNA vaccines.

How do public and private markets differ?
Governments, UNICEF, and Gavi buy large volumes of pediatric vaccines for national programmes at low prices. Private markets in high-income countries pay higher prices for adult and travel vaccines. Pharmacies are increasingly important for adult vaccination in North America and Europe. Tender pricing for low-income countries is supported by tiered pricing arrangements. Public programmes buy large volumes at lower prices, while private markets pay higher prices.

What role does outbreak preparedness play?
Governments and organizations stockpile vaccines for diseases such as cholera, Ebola, mpox, and pandemic influenza, and invest in rapid-response platforms. Outbreaks of measles, meningitis, and other diseases trigger emergency campaigns. Global stockpiles for cholera, meningitis, and yellow fever are managed by international coordinating groups. Stockpiles and rapid-response platforms help countries prepare for outbreaks.

How important is regional manufacturing?
Many countries, especially in Africa, are investing in local vaccine manufacturing to improve supply security, supported by international partnerships. Technology transfer and regulatory capacity building are key to these efforts. African Union targets aim to raise the share of vaccines produced on the continent. Africa and Latin America are building local vaccine production.

Which diseases are the main targets?
Pneumococcal disease, influenza, shingles, HPV, meningococcal disease, RSV, measles, rotavirus, hepatitis, and diphtheria-tetanus-pertussis combinations are among the largest vaccine categories by value or volume. HPV vaccination is expanding in low- and middle-income countries with single-dose schedules. Pneumococcal, influenza, HPV, meningococcal, and RSV vaccines generate large revenues.

What challenges face the market?
Vaccine hesitancy, funding pressures for global immunization programmes, policy changes in recommendations, and price competition affect demand. Cold chain requirements create logistical challenges in low-income countries. Misinformation on social media has contributed to declining confidence in some countries. Vaccine hesitancy and changing recommendations affect uptake.

Which vaccines market segments are growing fastest?
RSV vaccines; higher-valency pneumococcal conjugate vaccines; meningococcal vaccines; adult and older-adult immunization; mRNA vaccines; and pharmacy distribution are the fastest-growing segments. Pharmacies administer a growing share of influenza, COVID-19, RSV, and shingles vaccines. Adult vaccines for RSV, shingles, and pneumococcal disease are among the fastest-growing segments, along with mRNA-based products and next-generation conjugate vaccines that cover more serotypes.

Market Dynamics: Vaccines Market

  • Pediatric vaccines providing a stable base: Around 110 million infants receive routine vaccines each year. Government programmes provide steady demand. Coverage gaps remain in some regions.
  • Adult vaccines driving value: Shingles, RSV, and pneumococcal vaccines for adults are growing. Higher prices support value. RSV and shingles vaccines lead adult growth.
  • New product launches: New conjugate and RSV vaccines expand protection. They create new revenue streams. Launches expand the addressable population.
  • Outbreaks creating demand spikes: Meningitis and measles outbreaks increase vaccine demand. Emergency stockpiles are maintained. Outbreaks also expose coverage gaps.
  • mRNA platform development: mRNA vaccines are being developed for many diseases. Adoption beyond COVID-19 is progressing. mRNA allows rapid design of new vaccines.
  • Regional manufacturing investment: Countries invest in local production. This improves supply resilience. Local production improves access.
  • Combination vaccines: Combination products reduce visits and injections. They improve schedule compliance.
  • Tiered pricing: Prices differ by income level. This supports access in low-income countries.
  • Combination vaccines: Combination vaccines reduce the number of injections and simplify schedules.
  • Cold chain: Vaccine distribution requires reliable cold chains, especially in remote areas.
  • Therapeutic cancer vaccines: mRNA cancer vaccines are in late-stage trials.

Market Segmentation: Vaccines Market

By Technology
  • Live Attenuated Vaccines
  • Inactivated / Killed Vaccines
  • Subunit Vaccines
  • Recombinant Vaccines
  • Conjugate Vaccines
  • Toxoid Vaccines
  • Virus-Like Particle (VLP) Vaccines
  • Viral Vector Vaccines
  • mRNA Vaccines
  • DNA Vaccines
  • Protein-Based Vaccines
  • Other Emerging Vaccine Technologies
By Disease Indication
  • Bacterial Diseases
    • Pneumococcal Disease
    • Meningococcal Disease
    • Diphtheria
    • Tetanus
    • Pertussis
    • Tuberculosis (TB)
    • Typhoid
    • Cholera
    • Haemophilus Influenzae Type B (Hib)
  • Viral Diseases
    • Influenza
    • Human Papillomavirus (HPV)
    • Herpes Zoster (Shingles)
    • Respiratory Syncytial Virus (RSV)
    • Hepatitis A
    • Hepatitis B
    • Rotavirus
    • Varicella (Chickenpox)
    • Measles
    • Mumps
    • Rubella
    • Poliomyelitis (Polio)
    • COVID-19
    • Dengue
    • Japanese Encephalitis
    • Rabies
    • Yellow Fever
    • Tick-Borne Encephalitis
  • Parasitic Diseases
    • Malaria
    • Other Parasitic Infections
  • Combination Vaccine Indications
    • Diphtheria-Tetanus-Pertussis (DTP)
    • Measles-Mumps-Rubella (MMR)
    • DTaP-IPV-Hib
    • Other Combination Vaccines
  • Other Disease Indications
By Type
  • Monovalent Vaccines
  • Multivalent Vaccines
By Route of Administration
  • Parenteral Administration
    • Intramuscular (IM)
    • Subcutaneous (SC)
    • Intradermal (ID)
  • Oral Administration
  • Intranasal Administration
  • Other Routes of Administration
By Target Population
  • Pediatric Population
    • Neonates & Infants
    • Toddlers
    • Children
    • Adolescents
  • Adult Population
    • Young Adults
    • Middle-Aged Adults
    • Older Adults
  • Special Populations
By End User
  • Government Immunization Programs
    • National Immunization Programs
    • Public Health Vaccination Campaigns
  • Hospitals & Healthcare Facilities
    • Public Hospitals
    • Private Hospitals
    • Specialty Clinics
  • Vaccination Centers
    • Public Vaccination Centers
    • Private Vaccination Centers
  • Retail & Community Pharmacies
  • Other Healthcare Providers
By Product Category
  • Combination Vaccines
  • Single-Disease Vaccines
  • Seasonal Vaccines
  • Travel Vaccines
  • Therapeutic Vaccines
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Vaccines Market

  1. Ageing populations: Older adults need protection against respiratory diseases. Older adults face higher risks from respiratory infections. Older adults need more vaccines.
  2. Immunization programmes: Global goals aim to reach zero-dose children. Many children still miss routine doses. National programmes ensure baseline demand.
  3. Innovation: New vaccines target unmet needs. Pipeline products target RSV, CMV, and other diseases. New vaccines expand the market.
  4. Pharmacy vaccination: Convenient access raises adult uptake. Pharmacies offer walk-in vaccination. Pharmacies improve access.
  5. Pandemic preparedness: Governments invest in readiness. Stockpiles and platforms improve response speed.
  6. Disease outbreaks: Outbreaks in 57 countries in 2025 highlight measles risks. Measles outbreaks highlight coverage gaps. Outbreaks raise awareness.
  7. HPV programme expansion: Single-dose HPV schedules make programmes easier. More countries are introducing HPV vaccination.
  8. Travel vaccines: International travel supports demand for travel vaccines. Tourism recovery helps this segment.
  9. Expanded recommendations: Health authorities are broadening age and risk-group recommendations for several vaccines, which increases the number of people eligible for routine immunization.

Regional Outlook: Vaccines Market

  • North America: The United States is the largest vaccine market by value, driven by adult and pediatric vaccines and pharmacy distribution. Policy changes in recommendations are an uncertainty. Pharmacies administer most adult vaccines in the United States. Canada also funds broad adult immunization programmes. US recommendations shape demand.
  • Europe: Europe has strong public immunization programmes and growing adult vaccination. GSK reported meningitis vaccine growth in Europe. Several countries are expanding RSV and pneumococcal programmes. Several European countries added RSV vaccines for older adults. The UK added RSV vaccination for older adults. EU procurement supports supply.
  • Asia-Pacific: China, India, Japan, and Southeast Asia have large populations and major vaccine manufacturers, including the Serum Institute of India, the world’s largest by volume. The Serum Institute of India supplies vaccines to many countries. China is expanding its national immunization programme. India is a major producer.
  • Middle East & Africa: Africa has the largest number of under-vaccinated children and relies on Gavi and UNICEF support. Countries are investing in local manufacturing. Gulf countries have high coverage and growing adult vaccination. Gavi supports vaccine introduction across Africa. Nigeria and Ethiopia have large numbers of zero-dose children. Gavi supports African programmes.

Competitive Landscape: Vaccines Market

Key Players: Pfizer, GSK, Merck & Co., Sanofi, Moderna, AstraZeneca, CSL Seqirus, Serum Institute of India, Bharat Biotech, Sinovac Biotech, Novavax, Bavarian Nordic, Takeda, Biological E, Valneva

Consultant POV

The Vaccines Market’s steady 5.2% CAGR from USD 58.5 billion in 2025 toward approximately USD 97.1 billion by 2036 is anchored in routine immunization, adult vaccines, new products, and preparedness. Companies such as Pfizer, GSK, and Merck & Co. lead in adult and pediatric vaccines. Over the forecast period, adult vaccines and new technologies will drive growth, while funding and hesitancy remain challenges. Sustained funding for global immunization and clear public health recommendations will be critical to market growth. Companies with strong adult vaccine portfolios and new technology platforms are best placed for growth. Public funding will remain important. Sustained investment in manufacturing capacity, cold chain logistics, and public confidence in immunization will shape how quickly new vaccines reach the populations that need them.

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

Speak with an Analyst

    Download TOC